Transcriptional regulation of human Paraoxonase 1 by nuclear receptors

Chemico-Biological Interactions

Volumn 268, Issue , 2017, Pages 77-84

  Ponce Ruiz, N ^a   Murillo Gonzalez F E ^a   Rojas Garcia A E ^a   Mackness, Mike ^b   Bernal Hernandez Y Y ^a   Barron Vivanco B S ^a   Gonzalez Arias C A ^a   Medina Diaz I M ^a  

^a UNIVERSIDAD AUTÓNOMA DE NAYARIT   (Mexico)

^b Institute of Cardiovascular Sciences   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; ACETYLSALICYLIC ACID; AROMATIC HYDROCARBON RECEPTOR; ARYLDIALKYLPHOSPHATASE 1; CELL NUCLEUS RECEPTOR; CYTOCHROME P450; FIBRIC ACID DERIVATIVE; GLUCOCORTICOID RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYTYROSOL; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLYPHENOL; PREGNENOLONE X RECEPTOR; RESVERATROL; RETINOID X RECEPTOR; RIFAMPICIN; STEROL REGULATORY ELEMENT BINDING PROTEIN; SULFOSALICYLIC ACID; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; XENOBIOTIC AGENT; AHR PROTEIN, HUMAN; ARYLDIALKYLPHOSPHATASE; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CELL RECEPTOR; CYTOKINE; INTERLEUKIN 6; NFE2L2 PROTEIN, HUMAN; PON1 PROTEIN, HUMAN;

ATHEROSCLEROSIS; BIOTRANSFORMATION; CONFORMATIONAL TRANSITION; DNA METHYLATION; DRUG EFFICACY; EPIGENETICS; GENE EXPRESSION; GENE STRUCTURE; GLUCONEOGENESIS; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; LIGAND BINDING; NONHUMAN; OSTEOMALACIA; OXIDATIVE STRESS; PARAOXONASE 1 GENE; REVIEW; TRANSACTIVATION; TRANSCRIPTION REGULATION; XENOBIOTIC METABOLISM; ANIMAL; GENETIC EPIGENESIS; GENETICS; METABOLISM; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION INITIATION;

ANIMALS; ARYLDIALKYLPHOSPHATASE; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CYTOKINES; EPIGENESIS, GENETIC; HUMANS; INTERLEUKIN-6; NF-E2-RELATED FACTOR 2; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ARYL HYDROCARBON; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTIONAL ACTIVATION;

EID: 85014578999     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2017.02.005     Document Type: Review

References (81)

1. [1] Mackness, B., Durrington, P.N., Mackness, M.I., Human serum paraoxonase. Gen. Pharmacol. 31 (1998), 329–336.
2. [2] Han, C.Y., Chiba, T., Campbell, J.S., Fausto, N., Chaisson, M., Orasanu, G., et al. Reciprocal and coordinate regulation of serum amyloid A versus apolipoprotein A-I and paraoxonase-1 by inflammation in murine hepatocytes. Arterioscler. Thromb. Vasc. Biol. 26 (2006), 1806–1813.
3. [3] Mackness, M.I., Mackness, B., Durrington, P.N., Connelly, P.W., Hegele, R.A., Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr. OpinLipidol 7 (1996), 69–76.
4. [4] Costa, L.G., Giordano, G., Furlong, C.E., Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem. Pharmacol. 81 (2011), 337–344.
5. [5] Aviram, M., Billecke, S., Sorenson, R., Bisgaier, C., Newton, R., Rosenblat, M., et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler. Thromb. Vasc. Biol. 18 (1998), 1617–1624.
6. [6] Ahmed, S., Valen, E., Sandelin, A., Matthews, J., Dioxin increases the interaction between aryl hydrocarbon receptor and estrogen receptor alpha at human promoters. Toxicol. Sci. 111 (2009), 254–266.
7. [7] Draganov, D.I., La Du, B.N., Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedeb. Arch. Pharmacol. 369 (2004), 78–88.
8. [8] Teiber, J.F., Billecke, S.S., La Du, B.N., Draganov, D.I., Estrogen esters as substrates for human paraoxonases. Arch. Biochem. Biophys. 461 (2007), 24–29.
9. [9] Camps, J., Marsillach, J., Joven, J., The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit. Rev. Clin. Lab. Sci. 46 (2009), 83–106.
10. [10] Primo-Parmo, S.L., Sorenson, R.C., Teiber, J., La Du, B.N., The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33 (1996), 498–507.
11. [11] Huen, K., Yousefi, P., Street, K., Eskenazi, B., Holland, N., PON1 as a model for integration of genetic, epigenetic, and expression data on candidate susceptibility genes. Environ. Epigenet., 1, 2015 pii: dvv003.
12. [12] Clendenning, J.B., Humbert, R., Green, E.D., Wood, C., Traver, D., Furlong, C.E., Structural organization of the human PON1 gene. Genomics 35 (1996), 586–589.
13. [13] La Du, B.N., Furlong, C.E., Reiner, E., Recommended nomenclature system for the paraoxonases. Chem. Biol. Interact. 119–120 (1999), 599–601.
14. [14] Deakin, S., Leviev, I., Brulhart-Meynet, M.C., James, R.W., Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position − 107, implicating the Sp1 transcription factor. Biochem. J. 372 (2003), 643–649.
15. [15] Deakin, S.I., Leviev, I., Guernier, S., James, R.W., Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler. Thromb. Vasc. Biol. 23 (2003), 2083–2089.
16. [16] Mackness, M., Mackness, B., Human paraoxonase-1 (PON1): gene structure and expression, promiscuous activities and multiple physiological roles. Gene 567 (2015), 12–21.
17. [17] Mackness, B., Turkie, W., Mackness, M., Paraoxonase-1 (PON1) promoter region polymorphisms, serum PON1 status and coronary heart disease. Arch. Med. Sci. 9 (2013), 8–13.
18. [18] Brophy, V.H., Hastings, M.D., Clendenning, J.B., Richter, R.J., Jarvik, G.P., Furlong, C.E., Polymorphismsin the human paraoxonase (PON1) promoter. Pharmacogenetics 11 (2001), 77–84.
19. [19] Blatter-Garin, M.C., James, R.W., Dussoix, P., Blanche, H., Passa, P., Froguel, P., Ruiz, J., Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J. Clin. Invest. 99 (1997), 62–66.
20. [20] Leviev, I., Negro, F., James, R.W., Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler. Thromb. Vasc. Biol. 17 (1997), 2935–2939.
21. [21] Leviev, I., James, R.W., Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler. Thromb. Vasc. Biol. 20 (2000), 516–521.
22. [22] Suehiro, T., Nakamura, T., Inoue, M., Shiinoki, T., Ikeda, Y., Kumon, Y., et al. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis 150 (2000), 295–298.
23. [23] Costa, L.G., Vitalone, A., Cole, T.B., Furlong, C.E., Modulation of paraoxonase 1 (PON1) activity. Biochem. Pharmacol. 69 (2005), 541–550.
24. [24] Huen, K., Barcellos, L., Beckman, K., Rose, S., Eskenazi, B., Holland, N., Effects of PON polymorphisms and haplotypes on molecular phenotype in mexican-american mothers and children. Environ. Mol. Mutagen 52 (2011), 105–116.
25. [25] Précourt, L.F., Amre, D., Denis, M.C., Lavoie, J.C., Delvin, E., Seidman, E., et al. The three-gene paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis 214 (2011), 20–36.
26. [26] Schrader, C., Rimbach, G., Determinants of paraoxonase 1 status: genes, drugs and nutrition. Curr. Med. Chem. 18 (2011), 5624–5643.
27. [27] Kim, N.S., Kang, B.K., Cha, M.H., Oh, S.M., Ko, M.M., Bang, O.S., Association between PON1 5′-regulatory region polymorphisms, PON1 activity and ischemic stroke. Clin. Biochem. 42 (2009), 857–863.
28. [28] Arii, K., Suehiro, T., Ikeda, Y., Kumon, Y., Inoue, M., Inada, S., et al. Role of protein kinase C in pitavastatin-induced human paraoxonase I expression in Huh7 cells. Metabolism 59 (2010), 1287–1293.
29. [29] Garige, M., Gong, M., Varatharajalu, R., Lakshman, M.R., Quercetin up regulates paraoxonase 1 gene expression via sterol regulatory element binding protein 2 that translocates from the endoplasmic reticulum to the nucleus where it specifically interacts with sterol responsive element-like sequence in paraoxonase 1 promoter in HuH7 liver cells. Metabolism 59 (2010), 1372–1378.
30. [30] Cheng, C.C., Hsueh, C.M., Liang, K.W., Ting, C.T., Wen, C.L., Hsu, S.L., Role of JNK and c-Jun signaling pathway in regulation of human serum paraoxonase1 gene transcription by berberine in human HepG2 cells. Eur. J. Pharmacol. 650 (2011), 519–525.
31. [31] Ponce-Ruiz, N., Rojas-García, A.E., Barrón-Vivanco, B.S., Elizondo, G., Bernal-Hernández, Y.Y., Mejía-García, A., et al. Transcriptional regulation of human paraoxonase 1 by PXR and GR in human hepatomacells. Toxicol. Vitro 30 (2015), 348–354.
32. [32] Kumar, R., Johnson, B.H., Thompson, E.B., Overview of the structural basis for transcription regulation by nuclear hormone receptors. Essays. Biochem. 40 (2004), 27–39.
33. [33] Krasowski, M.D., Reschly, E.J., Ekins, S., Intrinsic disorder in nuclear hormone receptors. J. Proteome. Res. 7 (2008), 4359–4372.
34. [34] Feng, W., Ribeiro, R.C., Wagner, R.L., Nguyen, H., Apriletti, J.W., Fletterick, R.J., Baxter, J.D., Kushner, P.J., West, B.L., Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 280 (1998), 1747–1749.
35. [35] Lee, J.W., Lee, Y.C., Na, S.Y., Jung, D.J., Lee, S.K., Transcriptional coregulators of the nuclear receptor superfamily: coactivators and corepressors. Cell. Mol. Life Sci. 58 (2001), 289–297.
36. [36] Tsai, M.J., O'Malley, B.W., Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 63 (1994), 451–486.
37. [37] Elizondo, G., Medina-Díaz, I.M., Nuclear receptors and CYP3A4 regulation: implications for drugs and endogenous metabolism. Xenobiotic metabolizing enzymes and xenobiotic receptors. Pharmacol. Toxicol. Aspects, 2010, 21–43 Transworld Research Network, ISBN: 978-81-7895-437-0.
38. [38] Patel, A., Zhang, S., Paramahamsa, M., Jiang, W., Wang, L., Moorthy, B., Shivanna, B., Leflunomide induces pulmonary and hepatic CYP1A enzymes via aryl hydrocarbon receptor. Drug. Metab. Dispos. 43 (2015), 1966–1970.
39. [39] Vogel, C.F., Khan, E.M., Leung, P.S., Gershwin, M.E., Chang, W.L., Wu, D., Haarmann-Stemmann, T., Hoffmann, A., Denison, M.S., Cross-talk between aryl hydrocarbon receptor and the inflammatory response: a role for nuclear factor-κB. J. Biol. Chem. 289 (2014), 1866–1875.
40. [40] Fernandez-Salguero, P., Pineau, T., Hilbert, D.M., McPhail, T., Lee, S.S., Kimura, S., et al. Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science 268 (1995), 722–726.
41. [41] Matikainen, T., Perez, G.I., Jurisicova, A., Pru, J.K., Schlezinger, J.J., Ryu, H.Y., et al. Aromatic hydrocarbon receptor-driven Bax gene expression is required for premature ovarian failure caused by biohazardous environmental chemicals. Nat. Genet. 28 (2001), 355–360.
42. [42] Denison, M.S., Soshilov, A.A., He, G., Degroot, D.E., Zhao, B., Exactly the same but different: promiscuity and diversity in the molecular mechanisms of action of the aryl hydrocarbon (dioxin) receptor. Toxicol. Sci. 124 (2011), 1–22.
43. [43] DeGroot, D.E., Hayashi, A., Denison, M.S., Lack of ligand-selective binding of the aryl hydrocarbon receptor to putative DNA binding sites regulating expression of Bax and paraoxonase 1 genes. Arch. Biochem. Biophys. 541 (2014), 13–20.
44. [44] Singh, K.P., Bennett, J.A., Casado, F.L., Walrath, J.L., Welle, S.L., Gasiewicz, T.A., Loss of aryl hydrocarbon receptor promotes gene changes associated with premature hematopoietic stem cell exhaustion and development of a myeloproliferative disorder in aging mice. Stem. Cells Dev. 23 (2014), 95–106.
45. [45] Zhang, L., Hatzakis, E., Nichols, R.G., Hao, R., Correll, J., Smith, P.B., et al. Metabolomics reveals that aryl hydrocarbon receptor activation by environmental chemicals induces systemic metabolic dysfunction in mice. Environ. Sci. Technol. 49 (2015), 8067–8077.
46. [46] Shen, H., Robertson, L.W., Ludewig, G., Regulation of paraoxonase 1 (PON1) in PCB 126-exposed male Sprague dawleyrats. Toxicol. Lett. 209 (2012), 291–298.
47. [47] Shen, H., Li, M., Wang, B., Lai, I.K., Robertson, L.W., Ludewig, G., Dietary antioxidants (selenium and N-acetylcysteine) modulate paraoxonase 1 (PON1) in PCB 126-exposed rats. Environ. Sci. Pollut. Res. Int. 21 (2014), 6384–6399.
48. [48] Shen, H., Robertson, L.W., Ludewig, G., Regulatory effects of dioxin-like and non-dioxin-like PCBs and other AhR ligands on the antioxidant enzymes paraoxonase 1/2/3. Environ. Sci. Pollut. Res. Int. 23 (2015), 2108–2118.
49. [49] Santanam, N., Parthasarathy, S., Aspirin is a substrate for paraoxonase-like activity: implications in atherosclerosis. Atherosclerosis 191 (2007), 272–275.
50. [50] Jaichander, P., Selvarajan, K., Garelnabi, M., Parthasarathy, S., Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. J. Lipid Res. 49 (2008), 2142–2148.
51. [51] Gouédard, C., Barouki, R., Morel, Y., Dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptor-dependent mechanism dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptor-dependent mechanism. Mol. Cell. Biol. 24 (2004), 5209–5222.
52. [52] Guyot, E., Coumoul, X., Chasse, J.F., Khallouki, F., Savouret, J.F., Poirot, M., et al. Identification of a new stilbene-derived inducer of paraoxonase 1 and ligand of the aryl hydrocarbon receptor. Biochem. Pharmacol. 83 (2011), 627–632.
53. [53] Dail, M.B., Pickin, R., Crow, J.A., Chambers, J.E., The effect of in vitro dieldrin exposure on the rat paraoxonase 1 (pon1) promoter. J. Biochem. Mol. Toxicol. 28 (2014), 224–231.
54. [54] Kliewer, S.A., Goodwin, B., Willson, T.M., The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr. Rev. 23 (2002), 687–702.
55. [55] Blumberg, B., Sabbagh, W.J., Juguilon, H., Bolado, J.J., van Meter, C.M., Ong, E.S., et al. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev. 12 (1998), 3195–3205.
56. [56] Coumoul, X., Diry, M., Barouki, R., PXR-dependent induction of human CYP3A4 gene expression by organochlorine pesticides. Biochem. Pharmacol. 64 (2002), 1513–1519.
57. [57] Marketon, J.I., Sternberg, E.M., The glucocorticoid receptor: a revisited target for toxins. Toxins (Basel) 2 (2010), 1357–1380.
58. [58] Pascussi, J.M., Drocourt, L., Gerbal-Chaloin, S., Fabre, J.M., Maurel, P., Vilarem, M.J., Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Eur. J. Biochem. 268 (2001), 6346–6357.
59. [59] Camps, J., García-Heredia, A., Rull, A., Alonso-Villaverde, C., Aragonès, G., Beltrán-Debón, R., et al. PPARs in regulation of paraoxonases: control of oxidative stress and inflammation pathways. PPAR Res., 2012, 2012 (Article ID616371, 10 pages).
60. [60] Gouédard, C., Koum-Besson, N., Barouki, R., Morel, Y., Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol. Pharmacol. 63 (2003), 945–956.
61. [61] Tomás, M., Sentí, M., García-Faria, F., Vila, J., Torrents, A., Covas, M., et al. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 20 (2000), 2113–2119.
62. [62] Harangi, M., Seres, I., Varga, Z., Emri, G., Szilvássy, Z., Paragh, G., et al. Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage. Eur. J.Clin. Pharmacol. 60 (2004), 685–691.
63. [63] Kassai, A., Illyés, L., Mirdamadi, H.Z., Seres, I., Kalmár, T., Audikovszky, M., et al. The effect of atorvastatin therapy on lecithin:cholesterolacyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase. Clin. Biochem. 40 (2007), 1–5.
64. [64] Mirdamadi, H.Z., Sztanek, F., Derdak, Z., Seres, I., Harangi, M., Paragh, G., The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. Br. J. Clin. Pharmacol. 66 (2008), 366–374.
65. [65] Shen, Y., Wu, H., Wang, C., Shao, H., Huang, H., Jing, H., et al. Simvastatin attenuates cardiopulmonary bypass-induced myocardial inflammatory injury in rats by activating peroxisome proliferator-activated receptor γ. Eur. J. Pharmacol. 649 (2010), 255–262.
66. [66] Bergheanu, S.C., Van Tol, A., Dallinga-Thie, G.M., Liem, A., Dunselman, P.H., Van der Bom, J.G., et al. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol. Curr. Med. Res. Opin. 23 (2007), 2235–2240.
67. [67] Khateeb, J., Kiyan, Y., Aviram, M., Tkachuk, S., Dumler, I., Fuhrman, B., Urokinase-type plasminogen activator downregulatesparaoxonase 1 expression in hepatocytes by stimulating peroxisome proliferator-activated receptor-γ nuclear export. Arterioscler. Thromb. Vasc. Biol. 32 (2012), 449–458.
68. [68] Marsillach, J., Camps, J., Ferré, N., Beltran, R., Rull, A., Mackness, B., et al. Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease. BMC Gastroenterol., 14, 2009, 3.
69. [69] Bayram, B., Ozcelik, B., Grimm, S., Roeder, T., Schrader, C., Ernst, I.M., et al. A diet rich in olive oil phenolics reduces OxidativeStress in the heart of SAMP8 mice by induction of Nrf2-dependent gene expression. Rejuvenation Res. 15 (2012), 71–81.
70. [70] Geismann, C., Arlt, A., Sebens, S., Schäfer, H., et al. Cytoprotection “gone astray”: Nrf2 and its role in cancer. Onco. Targets Ther. 7 (2014), 1497–1518.
71. [71] Wu, B., Wang, F., Zhou, J., Hou, Y., Hong, G., Zhao, G., et al. Effect of PON1 overexpression on mouse diaphragmatic muscle cells injury caused by acute dichlorvos poisoning. Zhonghua Yi Xue Za Zhi 95 (2015), 2955–2959.
72. [72] Guo, R., Chen, L., Lian, J., Wu, B., Hong, G., Ge, Y., et al. The protective effect of regulation of paraoxonase 1 gene on liver oxidative stress injury induced by dichlorvos poisoning in mice. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 27 (2015), 285–290.
73. [73] Esatbeyoglu, T., Ulbrich, K., Rehberg, C., Rohn, S., Rimbach, G., Thermal stability, antioxidant, and anti-inflammatory activity of curcumin and its degradation product 4-vinyl guaiacol. Food Funct. 6 (2015), 887–893.
74. [74] Esatbeyoglu, T., Wagner, A.E., Motafakkerazad, R., Nakajima, Y., Matsugo, S., Rimbach, G., et al. Free radical scavenging and antioxidant activity of betanin: electron spin resonance spectroscopy studies and studies in cultured cells. Food Chem. Toxicol. 73 (2014), 119–126.
75. [75] Wagner, A.E., Boesch-Saadatmandi, C., Breckwoldt, D., Schrader, C., Schmelzer, C., Döring, F., et al. Ascorbic acid partly antagonizes resveratrol mediated heme oxygenase-1 but not paraoxonase-1 induction in cultured hepatocytes -role of the redox-regulated transcription factor Nrf2. BMC Complement. Altern. Med. 11 (2011), 1472–6882.
76. [76] Yeager, R.L., Reisman, S.A., Aleksunes, L.M., Klaassen, C.D., Introducing the TCDD-inducible AhR-Nrf2 gene battery. Toxicol. Sci. 111 (2009), 238–246.
77. [77] Kumon, Y., Suehiro, T., Ikeda, Y., Hashimoto, K., Human paraoxonase-1 gene expression by HepG2 cells is downregulated by interleukin-1βand tumor necrosis factor-α, but is upregulated by interleukin-6. Life Sci. 73 (2003), 2807–2815.
78. [78] Cheng, C.C., Hsueh, C.M., Chen, C.Y., Chen, T.H., Hsu, S.L., Interleukin-6 upregulates paraoxonase 1 gene expression via an AKT/NF-κB-dependent pathway. Biochem. Bioph. Res. Co. 437 (2013), 55–61.
79. [79] Tammen, S.A., Friso, S., Choi, S.W., Epigenetics: the link between nature and nurture. Mol. Asp. Med. 34 (2013), 753–764.
80. [80] Gotoh, S., Negishi, M., Statin-activated nuclear receptor PXR promotes SGK2 dephosphorylation by scaffolding PP2C to induce hepatic gluconeogenesis. Sci. Rep., 22(5), 2015, 14076.
81. [81] Shah, S.C., Sharma, R.K., Hemangini, Chitle A.R., Rifampicin induced osteomalacia. Tubercle 62 (1981), 207–209.